TransMedics Group, Inc. (TMDX) saw its stock price soar 5.39% in the post-market trading session on Monday, following the company's robust response to an inaccurate and misleading short-seller report issued by Scorpion Capital.
In a statement, TransMedics vehemently denied the claims made in the report, asserting that it failed to accurately represent the company's business, technology, diverse culture, and steadfast focus on delivering exceptional products and services for organ transplantation. The company defended the integrity of its practices, world-class team, compliance with applicable laws, and unwavering commitment to improving clinical outcomes.
TransMedics highlighted that its OCS technology and NOP program have enabled over 7,000 organ transplants, allowing surgeons to confidently utilize donor organs that would have otherwise been unutilized due to historical technology and logistics limitations. The company's technology and services have driven an expansion in overall U.S. transplant volumes and exceptional post-transplant clinical outcomes, as validated by its extensive clinical data set.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。